Amphastar PharmaceuticalsAMPH +2.59%83 Gross Margin % is 41.08% as of Mar. 2026, which is 5% below its 10-year median of 43.30. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.78 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 938 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks worse than 52.24% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Amphastar Pharmaceuticals had a gross margin of 41.08% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Amphastar Pharmaceuticals Gross Margin % Related Terms
Amphastar Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ETON, ESPR, BIOA: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Amphastar Pharmaceuticals (AMPH) has a Gross Margin % of 41.08% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Amphastar Pharmaceuticals and its competitors. This is near median its historical median of 43.30. Over the past decade, Amphastar Pharmaceuticals' Gross Margin % has ranged from 36.31 to 54.49. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #490 out of 938 companies in the Drug Manufacturers industry, placing it in the top 52.2%.
Is Amphastar Pharmaceuticals' Gross Margin % too high?
Amphastar Pharmaceuticals' current Gross Margin % of 41.08% is near median its 10-year median of 43.30. Over the past 10 years, this metric has ranged from a low of 36.31 to a high of 54.49. The Drug Manufacturers industry median Gross Margin % is 48.44. Amphastar Pharmaceuticals' value of 41.08% is 15.2% below this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #490 out of 938 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Gross Margin % compare to ETON and ESPR?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #490 out of 938 companies for Gross Margin %. This places Amphastar Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 48.44. Amphastar Pharmaceuticals' value of 41.08% is 15.2% below this benchmark. Historically, Amphastar Pharmaceuticals' own Gross Margin % has ranged from 36.31 to 54.49 over the past decade. While the company's 10-year median is 43.30 vs. the industry median of 48.44, Amphastar Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current Gross Margin % of 41.08% is 15.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current Gross Margin % is 41.08%, which is near median its own 10-year median of 43.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.78, compared to a current price of $21.56 — trading 55.8% below its estimated fair value. The current Gross Margin % is 41.08%, which is near median its 10-year median of 43.30 and 15.2% below the Drug Manufacturers industry median of 48.44. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Gross Margin % is 41.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.56 is trading 55.8% below its estimated GF Value™ of $48.78.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Gross Margin %: 41.08% (near median its 10-year median of 43.30)
GF Value™: $48.78 vs. price of $21.56 (55.8% below fair value)
Industry Position: 15.2% below the Drug Manufacturers median (#490 of 938)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
